Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo. | Meijer et al. Clinical Sarcoma Research 2011 1 5 http content 1 1 5 CLINICAL SARCOMA RESEARCH RESEARCH Open Access Expression of aromatase and estrogen receptor alpha in chondrosarcoma but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo Danielle Meijer1 Hans Gelderblom2 Marcel Karperien3 Anne-Marie Cleton-Jansen1 Pancras CW Hogendoorn1 and Judith VMG Bovée1 Abstract Background Chondrosarcomas are malignant cartilage-forming tumors which are highly resistant to conventional chemotherapy and radiotherapy. Estrogen signaling is known to play an important role in proliferation and differentiation of chondrocytes and in growth plate regulation at puberty. Our experiments focus on unraveling the role of estrogen signaling in the regulation of neoplastic cartilage growth and on interference with estrogen signaling in chondrosarcomas in vitro and in vivo. Methods We investigated the protein expression of estrogen receptor alpha ESR1 androgen receptor AR and aromatase in tumor specimens of various chondrosarcoma subtypes and primary chondrosarcoma cultures. Doseresponse curves were generated of conventional central chondrosarcoma cell lines cultured in the presence of 17p-estradiol dihydrotestosterone 4-androstene-3 17 dione 4-hydroxytamoxifen fulvestrant and aromatase inhibitors. In a pilot series the effect of anastrozole n 4 or exemestane n 2 treatment in 6 chondrosarcoma patients with progressive disease was explored. Results We showed protein expression of ESR1 and aromatase in a large majority of all subtypes. Only a minority of the tumors showed few AR positive cells. The dose-response assays showed no effect of any of the compounds on proliferation of conventional chondrosarcoma in vitro. The median progression-free survival of the patients treated with aromatase inhibitors did not significantly deviate from untreated patients. Conclusions The presence of ESR1 and aromatase in chondrosarcoma tumors and
